These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23073173)

  • 21. Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients.
    Sekino Y; Oue N; Mukai S; Shigematsu Y; Goto K; Sakamoto N; Sentani K; Hayashi T; Teishima J; Matsubara A; Yasui W
    Prostate; 2019 Feb; 79(2):234-242. PubMed ID: 30324761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
    Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
    Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
    Liu C; Armstrong CM; Lou W; Lombard AP; Cucchiara V; Gu X; Yang JC; Nadiminty N; Pan CX; Evans CP; Gao AC
    Mol Cancer Ther; 2017 Aug; 16(8):1521-1530. PubMed ID: 28500234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2.
    Fernandez A; Udagawa T; Schwesinger C; Beecken W; Achilles-Gerte E; McDonnell T; D'Amato R
    J Natl Cancer Inst; 2001 Feb; 93(3):208-13. PubMed ID: 11158189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.
    Ishikura N; Kawata H; Nishimoto A; Nakamura R; Ishii N; Aoki Y
    Prostate; 2010 Apr; 70(5):457-66. PubMed ID: 19902465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis.
    Goc A; Kochuparambil ST; Al-Husein B; Al-Azayzih A; Mohammad S; Somanath PR
    BMC Cancer; 2012 Sep; 12():409. PubMed ID: 22974127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C.
    Li J; Xiang S; Zhang Q; Wu J; Tang Q; Zhou J; Yang L; Chen Z; Hann SS
    J Exp Clin Cancer Res; 2015 May; 34(1):46. PubMed ID: 25971429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination therapy of antiandrogen and XIAP inhibitor for treating advanced prostate cancer.
    Danquah M; Duke CB; Patil R; Miller DD; Mahato RI
    Pharm Res; 2012 Aug; 29(8):2079-91. PubMed ID: 22451249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.
    Zhu Y; Liu C; Armstrong C; Lou W; Sandher A; Gao AC
    Clin Cancer Res; 2015 Sep; 21(18):4133-42. PubMed ID: 25995342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FAM3B/PANDER inhibits cell death and increases prostate tumor growth by modulating the expression of Bcl-2 and Bcl-X
    Maciel-Silva P; Caldeira I; de Assis Santos I; Carreira ACO; Siqueira FR; Antonioli E; Goldberg AC; Belizário JE; Garay-Malpartida HM
    BMC Cancer; 2018 Jan; 18(1):90. PubMed ID: 29357840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoxia selects for androgen independent LNCaP cells with a more malignant geno- and phenotype.
    Butterworth KT; McCarthy HO; Devlin A; Ming L; Robson T; McKeown SR; Worthington J
    Int J Cancer; 2008 Aug; 123(4):760-8. PubMed ID: 18512241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
    Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
    Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models.
    Bordini J; Morisi F; Elia AR; Santambrogio P; Pagani A; Cucchiara V; Ghia P; Bellone M; Briganti A; Camaschella C; Campanella A
    Clin Cancer Res; 2020 Dec; 26(23):6387-6398. PubMed ID: 32928793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer.
    Festuccia C; Gravina GL; Muzi P; Pomante R; Ventura L; Vessella RL; Vicentini C; Bologna M
    Endocr Relat Cancer; 2007 Sep; 14(3):601-11. PubMed ID: 17914091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential mechanisms of bicalutamide-induced apoptosis in prostate cell lines.
    Floyd MS; Teahan SJ; Fitzpatrick JM; Watson RW
    Prostate Cancer Prostatic Dis; 2009; 12(1):25-33. PubMed ID: 18475288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer.
    Colquhoun AJ; Venier NA; Vandersluis AD; Besla R; Sugar LM; Kiss A; Fleshner NE; Pollak M; Klotz LH; Venkateswaran V
    Prostate Cancer Prostatic Dis; 2012 Dec; 15(4):346-52. PubMed ID: 22614062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor.
    Carter SL; Centenera MM; Tilley WD; Selth LA; Butler LM
    BMC Cancer; 2016 Feb; 16():141. PubMed ID: 26907477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Downmodulation of Bcl-2 sensitizes metastatic LNCaP-LN3 cells to undergo apoptosis via the intrinsic pathway.
    Song R; Harris LD; Pettaway CA
    Prostate; 2010 May; 70(6):571-83. PubMed ID: 19938012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bicalutamide inhibits androgen-mediated adhesion of prostate cancer cells exposed to ionizing radiation.
    Wang T; Alavian MR; Goel HL; Languino LR; Fitzgerald TJ
    Prostate; 2008 Dec; 68(16):1734-42. PubMed ID: 18729104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.